Jessica Oakes
Medical · Monroe, NYNPI 1881945343
Payments from drug & device makers
Across 349 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$780
- Genentech USA, Inc.$530
- CSL Behring$497
- Sanofi$436
- Novartis$427
- plus $3K from 21 others
What the payments were for
- Food & beverage$6,21997%
- Education$2123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $1,008 |
| GSK | 56 | $780 |
| Genentech USA, Inc. | 37 | $530 |
| CSL Behring | 22 | $497 |
| Sanofi | 21 | $436 |
| Novartis | 25 | $427 |
| Kaleo, Inc. | 21 | $407 |
| Regeneron Healthcare Solutions, Inc. | 15 | $334 |
| Biocryst US Sales Co., LLC | 10 | $228 |
| Pfizer | 16 | $213 |
| Amgen(2 entities) | 14 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $208 |
| Pharming Healthcare, Inc. | 8 | $187 |
| Optinose US, Inc. | 9 | $166 |
| Sanofi-aventis U.S. LLC | 2 | $156 |
| Covis Pharma GmbH | 8 | $136 |
| Grifols USA, LLC | 5 | $99 |
| Boehringer Ingelheim | 5 | $96 |
| Alk-abello, Inc | 4 | $75 |
| Incyte Corporation | 3 | $50 |
| Blueprint Medicines Corporation | 2 | $50 |
| Merck | 3 | $46 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| LEO Pharma Inc. | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$109
How this compares
$6,432 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $96,925 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $12,931 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,408 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,592 |
| Fluticasone Propionate | 46 | $628 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $596 |
| Azelastine Hcl | 24 | $340 |
| Levocetirizine Dihydrochloride | 16 | $165 |
| Montelukast Sodium | 18 | $142 |
Paid to pharmacies, not to this prescriber.
Other medical in Monroe
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.